| 000 | 01718 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515001710.0 | ||
| 264 | 0 | _c20051027 | |
| 008 | 200510s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.2005.02.3176 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKlumpp, Thomas R | |
| 245 | 0 | 0 |
_aR-CHOP for mantle cell lymphoma. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cSep 2005 |
||
| 300 |
_a6802; author reply 6802-3 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comment; Comparative Study; Letter; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPrednisolone _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xtherapeutic use |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 23 _gno. 27 _gp. 6802; author reply 6802-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2005.02.3176 _zAvailable from publisher's website |
| 999 |
_c15802521 _d15802521 |
||